# Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)

> **NCT04607005** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 169 (actual)

## Conditions studied

- Nasal Polyps

## Interventions

- **DRUG:** Mepolizumab
- **DRUG:** Placebo
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT04607005
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-22
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-04-12
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2024-11-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607005, "Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04607005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*